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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2015, KaohsiuAbstract The aim of this study was to evaluate the predictive role of percentage of free
prostate-specific antigen (%fPSA) cut-points in prostate cancer (PCa) detection in patients with
total PSA (tPSA) levels between 2.5 ng/mL and 10.0 ng/mL. In total, 1321 consecutive initial
transrectal ultrasound (TRUS)-guided 12-core biopsies performed between 2005 and 2011 were
evaluated retrospectively. Benign pathologies, high-grade prostatic intraepithelial neoplasia,
and atypical small acinary proliferations were categorized as noncancerous (benign), and pros-
tate adenocarcinomas were categorized as cancerous (malignant). The patients were catego-
rized according to: Catalona’s published %fPSA categories (<10%, 10e15%, 15e20%, 20e25%,
or > 25%); digital rectal examination (DRE) results [benign (negative) or suspicious of malig-
nancy (positive)]. There was a significant relationship between the %fPSA cut-points and detec-
tion of PCa in DRE-negative patients. The presence of a 10% cut-point increased the probability
of PCa threefold. The %fPSA was significantly more related to PCa than the tPSA value in
receiver operating characteristic (ROC) curve analyses (p Z 0.001). Based on our findings, a
lower %fPSA, especially <10%, is an important parameter when deciding whether to perform
a biopsy on patients with a tPSA between 2.5 ng/mL and 10 ng/mL.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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Table 1 Demographics and patient characteristics ac-
cording to biopsy pathology.
Benign
(n Z 419)
Malignant
(n Z 186)
p
Median age (y) 64 (IQR 58e70) 66 (IQR 60e73) 0.009
Median PV (cm3) 54 (IQR 40e72) 40 (IQR 30e57) < 0.001
Median fPSA
(ng/mL)
1.18
(IQR 0.87e1.67)
1.00
(IQR 0.72e1.40)
< 0.001
Median tPSA
(ng/mL)
6.21
(IQR 5.10e7.82)
6.60
(IQR 5.29e7.98)
0.313
Median %fPSA 19 (IQR 15e26) 16 (IQR 11e22) < 0.001
%fPSA Z percentage of free prostate specific antigen;
fPSA Z free prostate-specific antigen; IQR Z interquartile
range; PV Z prostate volume; tPSA Z total prostate-specific
antigen.
316 H. Yilmaz et al.Introduction
Prostate-specific antigen (PSA)-based screening for the
detection of prostate cancer (PCa) is not routinely recom-
mended based on the current evidence, and indications for
prostate biopsy are not standardized in patients with
benign digital rectal examination (DRE) findings [1,2]. The
main problem is the lack of biochemical markers, including
PSA, capable of detecting PCa with high specificity and
sensitivity. Since the 1990s, when PSA was first used in PCa
screening, many studies have evaluated the usefulness of
PSA in detecting PCa and avoiding unnecessary prostate
biopsies. The total PSA (tPSA) level alone is not very reli-
able due to its low specificity, and additional parameters
have been developed to increase the efficiency of PSA. The
percentage of free PSA (%fPSA) may be the most important
of these potential markers.
When using classical sextant biopsies in 1998, Catalona
et al [3] reported that the probability of PCa increased as
the %fPSA decreased; the probability of PCa reached 56%
when the %fPSA was < 10%. However, prostate biopsy in-
dications have been revised several times in the past
decade in an effort to detect more PCa. Generally, the PSA
threshold has been decreased from 4 ng/mL to 2.5 ng/mL
[4e7], and the minimum optimal number of biopsy cores
has been increased from the classical sextant to between
eight and 10 [8]. The aim of this study was to evaluate the
predictive role of a %fPSA cut-point in PCa detection using
current prostate biopsy guidelines.
Materials and methods
The data obtained from 1321 consecutive initial transrectal
ultrasound (TRUS)-guided 12-core prostate biopsies per-
formed between 2005 and 2011 on patients with a tPSA be-
tween 2.5 ng/mL and 10.0 ng/mL were evaluated
retrospectively. Age, tPSA, fPSA before biopsy, DRE results,
and calculated prostate volume (PV; using the ellipse
method: length  depth  width  p/6) were noted. Benign
pathologies, high-grade prostatic intraepithelial neoplasia,
and atypical small acinary proliferations were categorized as
noncancerous (benign), and prostate adenocarcinomas were
categorized as cancerous (malignant). Systematic 12-core
biopsies (from lateral and medial sagittal planes of the
prostate, from the base, mid and apex on the right and left
sides of the peripheral zone) were performed for all PV,
ages, or tPSA levels. Additional biopsies were obtained from
hypoechoic nodules if necessary. For standardization, the
patients with missing data, cancer diagnoses other than
prostate adenocarcinoma, or a total number of biopsy cores
of < or >12, as well as patients who had undergone previous
antiandrogen or 5-alfa reductase inhibitory treatment, or
prostatic radiation therapy were excluded. The remaining
605 patients were included in the study.
The patients were grouped according to Catalona’s
published %fPSA categories (< 10%, 10e15%, 15e20%,
20e25%, and > 25%) and DRE results [benign (negative),
suspicious of malignancy (positive)]. All of the biopsies
were evaluated by the same pathologist (BM). The tPSA and
fPSA levels were assessed using a Roche Elecsys kit Elecsys
System (Roche Diagnostics, Mannheim, Germany).Statistical analysis
All of the data were analyzed using the Statistical Package
for Social Science (SPSS) 17.0 statistical program (SPSS Inc.,
Chicago, IL, USA). The independent sample t test was used
to compare parametric variables, and the ManneWhitney
test was used to compare nonparametric variables. Spear-
man’s correlation test was used for correlations. The effi-
ciencies of the diagnostic tests were evaluated using
receiver operating characteristic (ROC) curves. ROC curve
analyses were performed using MedCalc v12.7.8 trial
version (MedCalc Software bvba, Ostend, Belgium; http://
www.medcalc.org; 2014). The area under the ROC curve
(AUC) summarized discriminative ability, with pairwise
testing using DeLong’s test. Univariate and multivariate
logistic regression (LR) analyses were performed. A p value
< 0.05 was considered significant.Results
The median age of the patients was 65 [interquartile range
(IQR), 59e71] years. The mean fPSA was 1.1 (IQR, 0.8e1.5)
ng/mL, mean tPSA was 6.3 (IQR, 5.1e7.8) ng/mL, and mean
PV was 49.9 (IQR, 36.2e69.1) cm3. The patient de-
mographics according to benign and malignant pathologies
are shown in Table 1. There was no significant difference
between the patients with benign and malignant biopsy
results in terms of tPSA. However, the PV, fPSA, and %fPSA
levels were significantly lower in patients with malignant
biopsy results compared with patients with benign biopsies
(Table 1).
The DRE was positive in 162 patients (27%). PCa was
found in 30.7% (186/605) of the entire cohort and 26% (115/
443) of the DRE-negative patients. There was an inverse
relationship between %fPSA and tPSA (r Z 0.12,
p Z 0.002); a direct relationship between %fPSA and age
(rZ 0.31, pZ 0.000); and a direct relationship between %
fPSA and PV (r Z 0.37, p Z 0.000).
When the sensitivity, specificity, and predictive value of
%fPSA cut-points were evaluated, it was found that the 10%
cut-point exhibited higher specificity and positive predic-
tive value in DRE-negative patients (Table 2). The estima-
tion was performed with only DRE-negative patients
Table 2 Sensitivity, specificity, and predictive values of
different percentage of free prostate-specific antigen (%
fPSA) cut-points in digital rectal examination (DRE)-nega-
tive patients.
% fPSA cut-points
10% 15% 20% 25%
Sensitivity (%) 21.7 40.9 70.4 83.5
Specificity (%) 91.7 76.8 46.3 29.0
Positive predictive value (%) 48.0 38.2 31.5 29.1
Negative predictive value (%) 76.9 78.7 81.7 83.3
Figure 1. Percentage of free prostate-specific antigen (%
fPSA) and total prostate-specific antigen (tPSA) levels analyzed
using receiver operating characteristic (ROC) curves.
Percentage of free PSA in deciding prostate biopsy 317because Catalona et al [3] based their cut-points on DRE-
negative patients. Regardless of all other factors, a posi-
tive DRE is an absolute biopsy indication.
Total PSA levels, age, and PV were evaluated with
different %fPSA cut-points using univariate LR analyses
(Table 3). All cut-points were assessed (positively or nega-
tively) as dichotomous variables. The use of the 10% cut-
point increased the probability of detecting PCa threefold
among DRE-negative patients. This cut-point did not pro-
duce such a significant effect in DRE-positive patients. In
addition, tPSA did not contribute significantly to the
detection of PCa (Table 3).
When tPSA and %fPSA were evaluated using the ROC
curve to detect PCa, the AUC was found to be 0.52 with
tPSA and 0.63 with %fPSA (Fig. 1). In the ROC curve ana-
lyses, the %fPSA was significantly more concordant with PCa
than tPSA (p Z 0.001).
In DRE-negative patients, when the presence of PCa was
distributed according to %fPSA cut-points, our results were
similar to those of Catalona et al [3] (Fig. 2).Discussion
The focus of the present study was not to define the ideal %
fPSA cut-off value but to re-evaluate the %fPSA cut-points
defined by Catalona et al [3] in our cohort under current
biopsy criteria. There were two main differences betweenTable 3 Univariate analyses for different percentage of free
presence of prostate cancer (PCa).
DRE negative
OR (95% CI) p
Univariate LR % fPSA 10 3.10 (1.71e5.60) < 0.001
% fPSA 15 2.29 (1.45e3.60) < 0.001
% fPSA 20 2.06 (1.30e3.24) 0.002
% fPSA 25 2.06 (1.19e3.56) 0.010
tPSA 1.06 (0.94e1.19) 0.335
Age 1.01 (0.98e1.04) 0.304
PV/10 * 1.32 (1.18e1.47) < 0.001
DRE
DRE Z digital rectal examination; % fPSA Z percentage of free pros
PV Z prostate volume; tPSA Z total prostate-specific antigen.
* 10 mL decline in prostate volume.our study and that of Catalona et al [3]. We defined the PSA
threshold value as 2.5 ng/mL instead of 4.0 ng/mL, and we
used 12 biopsy cores rather than six. Thus, we re-evaluated
a known effective parameter under current conditions.
Catalona et al [3] reported that the detection rate of PCa
was 56% in patients whose %fPSA values were < 10%; the
detection rate decreased dramatically with rising %fPSA
values (8% with %fPSA values above 25%) [3]. Overall cancer
detection rates were almost the same in Catalona’s and our
cohort (26% vs. 25%), however, we obtained prostate bi-
opsies in lower tPSA values. In the present study, although
we cannot perform the comparison in a head to head order
because of the lack of Catalona’s raw data, we found that
the detection rate of PCa was highest (48.1%) below the %
fPSA cut-off value of 10% and lowest (16.7%) above the cut-
off value of 25%, such as claimed by Catalona et al. Addi-
tionally, we found a similar, dramatic decrease in PCa
detection rates and accordingly rising cut-off values
(Fig. 2). However, our PCa rates were higher at different
cut-off values except at < 10%, compared with Catalona’s
PCa rates. This may be the result of the twofold higher core
numbers of our study than those of Catalona’s (standard 12
cores biopsy vs. sextant biopsy). Our PCa detection ratesprostate-specific antigen (% fPSA) cut-points according to
DRE positive Total
OR (95% CI) p OR (95% CI) p
1.90 (0.72e5.01) 0.194 2.63 (1.59e4.35) < 0.001
2.29 (1.17e4.46) 0.015 2.33 (1.61e3.37) < 0.001
2.45 (1.26e4.78) 0.008 2.18 (1.50e3.16) < 0.001
3.47 (1.57e7.67) 0.002 2.38 (1.52e3.72) < 0.001
0.99 (0.84e1.17) 0.984 1.04 (0.94e1.15) 0.390
1.03 (0.99e1.07) 0.127 1.02 (1.00e1.04) 0.010
1.17 (1.02e1.34) 0.025 1.27 (1.17e1.38) < 0.001
2.22 (1.52e3.24) < 0.001
tate-specific antigen; LR Z logistic regression; ORZ odds ratio;
Figure 2. Very similar percentages of free/total prostate-specific antigen ratio (f/t PSA%) categories shown in digital rectal
examination (DRE)-negative patients in a University of Kocaeli (KOU) cohort (12 biopsies) and the cohort reported by Catalona et al
[3] (6 biopsies). PCa Z prostate cancer.
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support the data in the Catalona et al study, published in
the late 1990s [3].
Sensitivity decreases and specificity increases as the %
fPSA cut-points decrease. In our study, we found 21.7%
sensitivity and 91.7% specificity with a 10% cut-point and
29.0% sensitivity and 83.5% specificity with a 25% cut-point.
Lee et al [9] reported that a 10% cut-point had 40% sensi-
tivity and 72% specificity within a 4e10 ng/mL PSA range in
their meta-analysis, composed of studies of which w 70%
were published before the 1990s. Furthermore, they found
a cut-point of 7% was associated with 92% specificity. In
another study that had similar inclusion criteria, Lee et al
[10] defined a 10% cut-point with 25% sensitivity and 85%
specificity, similar to our findings. In the study by Lee et al
[10], a cut-point of 7.5% was associated with 11% sensitivity
and 95% specificity. Auprich et al [11] found 65.1% speci-
ficity with a 15% cut-point in a repeated biopsy cohort of
127 patients.
Based on these findings, %fPSA cut-points were used
during PSA-based screening for PCa to make decisions
regarding further evaluation. During a public screening in
Japan, Kobori et al [12] observed a huge decrease in
referred patients when they added the 0.22 %fPSA cut-point
to the criteria for further evaluation without a significant
difference in the detection of PCa. Although it can be
useful in deciding whether to refer patients for further
evaluation during screening, a relatively high %fPSA cut-
point (0.22 in Kobori’s study) should not be used to make
a decision regarding prostate biopsy for a single patient due
to its low specificity at that level.
Many studies have evaluated the predictive value of %
fPSA using the AUC in a ROC curve analysis. Lee et al [9]
published a meta-analysis and reported that the average
AUC was 0.68 with %fPSA for the detection of PCa. Our
findings were similar, with a 0.63-AUC value, although in
the studies included in Lee’s meta-analysis, the PSA
threshold values were higher and the number of cores waslower than in our study. In addition, our study revealed a
48% positive predictive value of the 10% cut-point, indi-
cating that PCa would be detected in approximately half of
the people with a negative DRE and a %fPSA < 10%.
Furthermore, with univariate LR analyses, we found that
the probability of the detection of PCa increased threefold
when the %fPSA was < 10%. However, based on the uni-
variate analyses, the tPSA value was not significantly
correlated with PCa detection (Table 3).
Low PVs in patients with tPSA values between 2.0 ng/mL
and 10 ng/mL have been reported to be associated with
higher PCa detection rate [13e15]. The results of our study
support this statement (Table 1). Another remarkable
finding of the present study is that the median tPSA value
was similar in the benign and malignant groups and
therefore not correlated with PCa detection, as shown in
Table 1, and also in the univariate analyses in Table 3.
Consistent with this finding, Catalona et al [3] reported
median tPSA values of 5.6 ng/mL and 5.9 ng/mL in their
benign and cancer groups, respectively; these values were
not significantly different. Similar findings were reported
in a study of Chinese men with tPSA levels of 2.5e20 ng/mL
[16]. The men were divided into two groups based on their
tPSA value: 2.5e10 ng/mL and 10.1e20 ng/mL. In both
groups, there was no significant difference between those
with PCa and those without regarding the median tPSA. We
detected a lower median fPSA in the malignant group
(Table 1); however, none of the studies described above
compared fPSA alone in malignant and benign individuals
because the studies were focused on the %fPSA in in-
dividuals with PCa.
In conclusion, we believe that the effectiveness of %fPSA
remained significant as PSA threshold values decreased and
the number of cores increased over time. At least until a
better marker is found, a lower level of %fPSA, especially <
10%, should be considered as a strong indication for pros-
tate biopsy in patients with a tPSA level between 2.5 ng/mL
and 10 ng/mL.
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